Jingding Pharmaceuticals Global Patient Advisory Committee landed in China to promote patient-centered drug development.

On September 10, 2020, Parexel, a leading solution provider dedicated to accelerating the development and listing of innovative therapies at all stages of clinical development to commercialization to improve human health, recently announced the establishment of a Patient Advisory Committee in China and the first round table in Shanghai.
seven patients/patient families in the field of oncology and rare diseases participated as consultants to discuss ways to improve the patient's clinical trial experience with experts at Jingding Pharmaceuticals.
Global Patient Advisory Committee focuses on patient-centric drug development and aims to help increase patient engagement in clinical trials and accelerate the process at all stages of the drug development life cycle by gathering patient feedback. At the
conference, patients shared their experiences and feelings about participating in clinical trials, providing guidance and insights on a number of issues that affect patient participation experiences, including how to strengthen patient-patient communication in clinical trials, how patient organizations participate, the advantages of geographical coordination of clinical trial resources, and how to improve the patient reimbursement process. "For clinical developers, 'patient-centric' means we have to treat patients as partners in clinical research, not just as subjects," said Yang Liuqing, senior medical director of
Jingding Pharmaceuticals.
this requires us to listen to patients in a timely and adequate manner and understand their needs and challenges in the drug development process, thereby helping patients reduce the burden and barriers to participating in clinical trials.
" patient-centered drug development refers to the involvement of patients in the design and execution of trials designed to be close to the needs of patients, thereby encouraging patients to participate in trials.
A report by the Economist Intelligence Unit, commissioned by Jingding Pharmaceuticals, shows that a patient-centric strategy can significantly optimize the processes and outcomes of clinical trials and accelerate patient benefits from innovative drugs and therapies: in patient-centric trials, patient recruitment times are reduced by 40 percent and drug success rates are 19 percent higher.
to better integrate patient needs into the full life cycle of drug development, Synding Pharmaceuticals established the world's first Patient Advisory Board in the United States in December 2019 to build long-term relationships with patients in different disease areas.
Advisory Committee will hold regular meetings to gather the views and recommendations of patient consultants on topics related to drug development.
currently, Synding Pharmaceuticals has held four patient advisory board meetings in the United States and Europe, working closely with 20 patient consultants worldwide on a variety of clinical diseases, including oncology and rare diseases.
To help address the challenges patients face in clinical trials, Jingding Pharmaceuticals has been innovating to drive a patient-centric strategy," said Yajie Li, vice president (technology) of
Jingding Pharmaceutical Regulation Consulting.
, Jingding Pharmaceuticals will land a series of projects to achieve these goals.
believe that through the use of these humane services and innovative technologies, we can effectively optimize the patient experience and provide convenience and support to patients.
, a number of innovative drug development tools, including decentralized trials, were discussed, as well as how they can improve operational efficiency while taking into account patient convenience and safety.
, Jingding Pharmaceuticals has conducted (including completed and ongoing) more than 90 decentralized trials worldwide.
consulted with patient consultants at the meeting on how best to conduct decentralized trials in China. Chen Jiannan, vice president of
Jingding Pharmaceutical Information Technology Asia Pacific, said, "Although the implementation and promotion of decentralized trials is still in its infancy in China, through communication with patients, we can understand the views of Chinese patients on this innovative approach as early as possible, and help improve the design of the trial, so as to better serve patients in the future."
" Source: medsci!-- content presentation ends -- !-- determine if login ends.